Artificial Intelligence for breaST canceR scrEening in mAMmography (AI-STREAM)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

25008 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study aims to generate real-world evidence on the overall benefits and disadvantages of using Lunit INSIGHT MMG AI based CADe/x for breast cancer detection in a population-based breast cancer screening program in Korea.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Validation of an Artificial Intelligence Algorithm to Help Interpret Mammograms

NCT05640011

Breast Cancer

COMPLETED

Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer

NCT05615298

Breast Cancer

COMPLETED

Artificial Intelligence in Large-scale Breast Cancer Screening

NCT04778670

Breast Neoplasm Female

UNKNOWN NA

Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component

NCT07060599

Artificial Intelligence (AI) in Diagnosis

NOT_YET_RECRUITING NA

Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.

NCT06479772

Breast Cancer Female

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Several challenges have been identified in breast cancer screening: 1) Some breast cancer cases not identified through screening; 2) Excessive recalls for further testing; 3) Low sensitivity in dense breasts; 4) Inter-reader variability. AI-based CADe/x has been shown to improve radiologist performance and provides results equivalent or superior to those from radiologists alone.
2. This multicenter, prospective study involves women who visit sites for breast cancer screening in Korea. Women eligible for national cancer screening in the relevant year who read the study participant recruitment brochure and read and sign the Participant Information Sheet and Informed Consent Form will be recruited into this study. Approximately 32,714 participants will be enrolled from February 2021 through December 2022 at five study sites in Korea.
3. In Korea, a single radiologist performs mammogram readings. If recall is required (per usual care), further diagnostic work-up will be conducted to confirm cancer detected at screening. The national cancer registry databases will be reviewed in 2026 and 2027. Available findings will be recorded for all participants regardless of their screening status to identify study participants with breast cancer diagnosis within one year and within two years from screening.
4. In primary outcome measurement, as part of the standard screening procedure, mammograms will be read and recorded by a breast radiologist without AI-CADe/x, and then with AI-based CADe/x. \[Set1\]
5. In secondary outcome measurement, mammograms from the same participants as Set 1 will be read and recorded by a general radiologist without AI-based CADe/x, and then with AI-based CADe/x. \[Set 2\] In additional secondary outcome measurement, arbitration reading will be conducted by another breast radiologist without AI-based CADe/x for cases in which the reading results of the two radiologists without AI-based CADe/x in Set 1 and Set 2 are inconsistent. \[Set 3\]
6. After completing the standard screening procedure in Set 1, several situational comparison groups \[Set2 and Set3\] for comparison the diagnostic accuracy will be performed independently and retrospectively The results from Set 2 and Set 3 will not impact the clinical decision(s) associated with the care of the study participants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

same as study population

Use of AI-based CADe/x by breast radiologists

Lunit INSIGHT MMG CADe/x for medical imaging

Intervention Type DEVICE

• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lunit INSIGHT MMG CADe/x for medical imaging

• A software that detects areas suspected of breast cancer using mammographic images, marks areas suspected of malignant lesions, and displays the probability of malignant lesions to assist with the interpreting physician's diagnosis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be eligible for national cancer screening in the relevant year and visit the site for breast cancer screening
* Provide consent for study participation using the Informed Consent Form and complete a Participant information Sheet

Exclusion Criteria

* Participants who meet any of the following criteria will be excluded from the study:
* Has a history of or current breast cancer
* Is currently pregnant or plans to become pregnant in the next 12 months
* Has a history of breast surgery (mammoplasty or insertion of a foreign substance, such as paraffin or silicon)
* Has mammography for diagnostic purposes

Minimum Eligible Age

40 Years

Maximum Eligible Age

100 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No